EUVIMEDEUVIMED entdecken
Video/AudioValidierungsstudie

Next-Generation Sequencing Clonality Assays: Clinical Validation for Minimal Residual Disease Monitoring in Multiple Myeloma

Shuiling Xie, Changfeng Liao, Liuyan Xin, Chuanming Lin

Journal of Visualized Experiments · 2026

DOI: 10.3791/69890 ↗

Kurz gefasst

Video/Audio in der Zeitschrift Journal of Visualized Experiments, 2026. Verfasst von Shuiling Xie und 3 weiteren Autor:innen. Beteiligte Einrichtung: The First Affiliated Hospital of Gannan Medical University. Hauptthemen laut MEDLINE: Multiple Myeloma, High-Throughput Nucleotide Sequencing.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Minimal residual disease (MRD) detection is crucial for managing lymphoid malignancies. This study introduces OriMIRACLE LTM, a novel next-generation sequencing (NGS)-based B-cell receptor (BCR) and T-cell receptor (TCR) clonality assay for MRD detection. We validated the assay using cell lines and clinical samples, including residual smears, from patients with Multiple Myeloma (MM). The BCR/TCR clonality assay demonstrated an over 90% positive detection rate in lymphoid malignancies. Validation studies in MM patients demonstrated an 81.36% (48/59) concordance rate between multicolor flow cytometry (MFC) and clinical response assessment in tumor cell detection. Notably, 61.11% (11/18) of MM patients positive for MRD by both NGS and MFC experienced disease progression or relapse. Patients with MRD detected solely by NGS exhibited lower clinical complete response rates, and some initially responsive MM patients relapsed after treatment cessation. These findings indicate that this NGS-based assay offers highly sensitive and specific MRD detection in lymphoid malignancies, even in MM patient-derived residual smear samples. It demonstrates advantages over MFC and proves valuable for MRD tracking. In conclusion, current evidence supports NGS as a complementary tool to MFC, particularly in MFC⁻/NGS⁺ patients, as NGS offers deeper risk stratification. However, the optimal intervention threshold remains to be determined by prospective studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaHigh-Throughput Nucleotide SequencingHumansNeoplasm, ResidualReceptors, Antigen, B-CellReceptors, Antigen, T-CellFlow CytometryCell Line, Tumor

Substanzen

Receptors, Antigen, B-CellReceptors, Antigen, T-Cell

Autor:innen und Institutionen

  • The First Affiliated Hospital of Gannan Medical University.
  • The First Affiliated Hospital of Gannan Medical University; lcm1430@163.com.

Zitieren

APA

Xie, S., Liao, C., Xin, L., & Lin, C. (2026). Next-Generation Sequencing Clonality Assays: Clinical Validation for Minimal Residual Disease Monitoring in Multiple Myeloma. Journal of Visualized Experiments. https://doi.org/10.3791/69890

Vancouver

Xie S, Liao C, Xin L, Lin C. Next-Generation Sequencing Clonality Assays: Clinical Validation for Minimal Residual Disease Monitoring in Multiple Myeloma. Journal of Visualized Experiments. 2026. doi:10.3791/69890

BibTeX
@article{Xie2026,
  author = {Xie, Shuiling and Liao, Changfeng and Xin, Liuyan and Lin, Chuanming},
  title = {Next-Generation Sequencing Clonality Assays: Clinical Validation for Minimal Residual Disease Monitoring in Multiple Myeloma},
  journal = {Journal of Visualized Experiments},
  year = {2026},
  doi = {10.3791/69890}
}
Kostenlos starten →